Literature DB >> 30158713

Participant-Related Risk Factors for False-Positive and False-Negative Fecal Immunochemical Tests in Colorectal Cancer Screening: Systematic Review and Meta-Analysis.

Clasine M de Klerk1, Lisanne M Vendrig1, Patrick M Bossuyt1, Evelien Dekker1.   

Abstract

OBJECTIVES: Colorectal cancer (CRC) screening using fecal immunochemical tests (FIT) may reduce CRC-related mortality but its effectiveness is influenced by the limited accuracy of FIT. Identifying individuals at increased risk of a false FIT result could improve screening, but the available evidence is conflicting. We performed a systematic review and meta-analysis on risk factors for false-positive and false-negative FIT results in CRC screening.
METHODS: A systematic search in MEDLINE, EMBASE, and Cochrane Library identified publications (before 29 January 2017) on risk factors (known at time of FIT invitation) associated with false FIT results (presence/absence of advanced neoplasia) in a CRC screening setting. Risk of bias was assessed using QUIPS. In meta-analysis, summary relative risk ratios and corresponding 95% confidence intervals were calculated for each risk factor.
RESULTS: Of 518 records identified, 14 studies with 54,499 participants in total were included for analysis. In meta-analysis, male sex was associated with a significantly lower risk of false-positivity (RR 0.84, CI 0.74-0.94), whereas participants using non-steroidal anti-inflammatory drugs (NSAIDs) had a higher risk (RR 1.16, CI 1.06-1.27). The use of anticoagulants was most frequently studied, without a significant effect on FIT positivity. Males (RR 1.83, CI 1.53-2.19), participants with a family history for CRC (RR 1.61, CI 1.19-2.15), hyperglycemia (RR 1.29, CI 1.02-1.65), hypertension (RR 1.50, CI 1.14-1.98), obesity (RR 1.38, CI 1.11-1.71), and (former) smokers (RR 1.93, CI 1.52-2.45) were all at significantly higher risk for false-negative results. Age was not found to have a systematic effect on either FIT false-positivity or false-negativity in meta-analysis.
CONCLUSIONS: Multiple risk factors, known at time of FIT invitation, are associated with false FIT results in CRC screening. This information can be used to identify populations risking false reassurance after a negative result or unnecessary colonoscopy after a positive result, and to further optimize CRC screening effectiveness.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30158713      PMCID: PMC6768609          DOI: 10.1038/s41395-018-0212-7

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  71 in total

1.  Detection rate of immunochemical fecal occult blood test for colorectal adenomatous polyps with severe dysplasia.

Authors:  H Nakama; A S Abdul Fattah; B Zhang; N Kamijo; K Fujimori; K Miyata
Journal:  J Gastroenterol       Date:  1997-08       Impact factor: 7.527

2.  Diagnostic Accuracy of a Qualitative Fecal Immunochemical Test Varies With Location of Neoplasia But Not Number of Specimens.

Authors:  Martin C S Wong; Jessica Y L Ching; Victor C W Chan; Thomas Y T Lam; Jeffrey P Shum; Arthur K C Luk; Sunny S H Wong; Siew C Ng; Simon S M Ng; Justin C Y Wu; Francis K L Chan; Joseph J Y Sung
Journal:  Clin Gastroenterol Hepatol       Date:  2015-02-24       Impact factor: 11.382

3.  Influence of sample return time and ambient temperature on the performance of an immunochemical faecal occult blood test with a new buffer for colorectal cancer screening.

Authors:  Vincent Dancourt; Samia Hamza; Sylvain Manfredi; Antoine Drouillard; Jeanne-Marie Bidan; Jean Faivre; Come Lepage
Journal:  Eur J Cancer Prev       Date:  2016-03       Impact factor: 2.497

4.  Seasonal variations do not affect the superiority of fecal immunochemical tests over guaiac tests for colorectal cancer screening.

Authors:  Sébastien Chausserie; Romuald Levillain; Josette Puvinel; Olivier Ferrand; Angela Ruiz; Thibaut Raginel; Olivier Lantieri; Guy Launoy; Lydia Guittet
Journal:  Int J Cancer       Date:  2014-09-18       Impact factor: 7.396

5.  Colorectal cancer risk in first-degree relatives of patients with colorectal adenomatous polyp.

Authors:  Hidenori Nakama; Kayoko Fukazawa
Journal:  Hepatogastroenterology       Date:  2002 Jan-Feb

6.  Characteristics of colorectal cancer with false negative result on immunochemical faecal occult blood test.

Authors:  H Nakama; N Kamijo; K Fujimori; A Horiuchi; A S Fattah; B Zhang
Journal:  J Med Screen       Date:  1996       Impact factor: 2.136

7.  Randomised study of screening for colorectal cancer with faecal-occult-blood test.

Authors:  O Kronborg; C Fenger; J Olsen; O D Jørgensen; O Søndergaard
Journal:  Lancet       Date:  1996-11-30       Impact factor: 79.321

8.  Combining risk factors with faecal immunochemical test outcome for selecting CRC screenees for colonoscopy.

Authors:  Inge Stegeman; Thomas R de Wijkerslooth; Esther M Stoop; Monique E van Leerdam; Evelien Dekker; Marjolein van Ballegooijen; Ernst J Kuipers; Paul Fockens; Roderik A Kraaijenhagen; Patrick M Bossuyt
Journal:  Gut       Date:  2013-08-20       Impact factor: 23.059

9.  Risk of progression of advanced adenomas to colorectal cancer by age and sex: estimates based on 840,149 screening colonoscopies.

Authors:  Hermann Brenner; Michael Hoffmeister; Christa Stegmaier; Gerhard Brenner; Lutz Altenhofen; Ulrike Haug
Journal:  Gut       Date:  2007-06-25       Impact factor: 23.059

10.  Sensitivity of immunochemical fecal occult blood test to small colorectal adenomas.

Authors:  Tamiya Morikawa; Jun Kato; Yutaka Yamaji; Ryoichi Wada; Toru Mitsushima; Kohsaku Sakaguchi; Yasushi Shiratori
Journal:  Am J Gastroenterol       Date:  2007-07-07       Impact factor: 10.864

View more
  9 in total

1.  Learning to be More Positive About FIT.

Authors:  Douglas J Robertson
Journal:  Am J Gastroenterol       Date:  2018-11-05       Impact factor: 10.864

2.  Colorectal cancer screening with fecal immunochemical testing: a community-based, cross-sectional study in average-risk individuals in Nigeria.

Authors:  Olusegun I Alatise; Anna J Dare; Patrick A Akinyemi; Fatimah B Abdulkareem; Samuel A Olatoke; Gregory C Knapp; T Peter Kingham
Journal:  Lancet Glob Health       Date:  2022-07       Impact factor: 38.927

3.  Urinary MicroRNA Sensing Using Electrochemical Biosensor to Evaluate Colorectal Cancer Progression.

Authors:  Sow-Neng Pang; Yu-Lun Lin; Yueh-Er Chiou; Wai-Hung Leung; Wen-Hui Weng
Journal:  Biomedicines       Date:  2022-06-17

4.  Proton-pump inhibitors are associated with a high false-positivity rate in faecal immunochemical testing.

Authors:  Gemma Ibáñez-Sanz; Núria Milà; Luisa C de la Peña-Negro; Montse Garcia; Carmen Vidal; Lorena Rodríguez-Alonso; Gemma Binefa; Francisco Rodríguez-Moranta; Victor Moreno
Journal:  J Gastroenterol       Date:  2020-11-07       Impact factor: 7.527

Review 5.  Cancer Prevention and Screening for Older Adults: Part 1. Lung, Colorectal, Bladder, and Kidney Cancer.

Authors:  Patrick P Coll; Beatriz Korc-Grodzicki; Benjamin T Ristau; Armin Shahrokni; Alexander Koshy; Olga T Filippova; Imran Ali
Journal:  J Am Geriatr Soc       Date:  2020-09-03       Impact factor: 7.538

6.  Thrombocytosis helps to stratify risk of colorectal cancer in patients referred on a 2-week-wait pathway.

Authors:  J A Bailey; N Hanbali; K Premji; J Bunce; S Mashlab; J A Simpson; D J Humes; A Banerjea
Journal:  Int J Colorectal Dis       Date:  2020-05-01       Impact factor: 2.571

7.  Positive Fecal Immunochemical Test or Cologuard in the Era of the Novel Coronavirus Disease-2019 Pandemic.

Authors:  Patrick E Young; Micheal Tadros; Sheena Mago
Journal:  Gastroenterology       Date:  2020-05-23       Impact factor: 22.682

8.  Predictive Modeling of Colonoscopic Findings in a Fecal Immunochemical Test-Based Colorectal Cancer Screening Program.

Authors:  Jade Law; Anand Rajan; Harry Trieu; John Azizian; Rani Berry; Simon W Beaven; James H Tabibian
Journal:  Dig Dis Sci       Date:  2021-08-04       Impact factor: 3.487

9.  Alternative diagnoses and demographics associated with a raised quantitative faecal immunochemical test in symptomatic patients.

Authors:  Mark S Johnstone; Gillian Miller; Grace Pang; Paul Burton; Georgios Kourounis; Jack Winter; Emilia Crighton; David Mansouri; Paul Witherspoon; Karen Smith; Stephen T McSorley
Journal:  Ann Clin Biochem       Date:  2022-03-03       Impact factor: 2.587

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.